Skip to main content
OpenTrials

Clinical trial condition

Digestive System Neoplasms

Explore clinical trials studying Digestive System Neoplasms. Study availability and eligibility vary by location and protocol.

14,257 public trials 3,235 recruiting studies
Refine in advanced search Browse all conditions

Digestive System Neoplasms trial results

Recruiting

Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods

NCT06515821

Conditions
Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, +9 more
Locations
  • Military Medical Academy Sofia, Gastroenterology Clinic, 3 Sveti Georgi Sofiiski str., Sofia 1606, Bulgaria Sofia, Bulgaria
  • University Specialised Hospital for Active Treatment of Oncology Departement of Gastroenterology. Sofia, Bulgaria
  • UFC: Université de Franche-Comté Oncology department CHU Besançon Besançon, France
  • MKI UKSH Lübeck Lübeck, Germany
View Trial Details
Recruiting

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

NCT02598349

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +6 more
Locations
  • University of Florida Proton Therapy Institute Jacksonville, Florida, United States
  • Northwestern Medicine Chicago Proton Center Warrenville, Illinois, United States
  • McLaren Proton Therapy Center Flint, Michigan, United States
  • Inova Schar Cancer Institute Fairfax, Virginia, United States
View Trial Details
Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674

Conditions
Adenoma, Adnexal Diseases, Breast Diseases, +75 more
Locations
  • City of Hope Duarte, California, United States
  • University of Southern California Los Angeles, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • University of Colorado School of Medicine Aurora, Colorado, United States
View all 17 locations
View Trial Details
Recruiting

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

NCT06682793

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +57 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • UCSD Moores Cancer Center La Jolla, California, United States
  • UCLA Medical Center Los Angeles, California, United States
  • Mayo Clinic Jacksonville, Florida, United States
View Trial Details

Related conditions